WHAT IS KNOWN AND OBJECTIVE: Community pharmacists have a key role to play in addressing drug misuse. The objective of this research was to systematically review the current evidence and investigate the attitudes and practice strategies of community pharmacists towards drug misuse management. METHODS: Data were extracted from 19 studies retrieved via a three-step search strategy using the Arksey and O'Malley methodological framework for conducting scoping reviews. RESULTS AND DISCUSSION: The attitudes and practice strategies of pharmacists towards drug misuse management and relevance to years of practice experience were discussed in seven of the 19 studies. Pharmacists reported gaps in knowledge and insufficient education and training on drug misuse-related topics. Barriers to the effective management of drug misuse included lack of time and staff training. The most commonly reported strategy to address drug misuse was referral back to the doctor. Eight of the studies identified the benefits of real-time prescription monitoring systems. Pharmacists have a key role to play in addressing drug misuse. Opportunities exist in the development of new and innovative approaches for harm minimization led by pharmacists, and in the examination and evaluation of the pharmacists' role in referral services, interventions and screening. WHAT IS NEW AND CONCLUSION: It is important to consider the role and contribution of early career pharmacists in the delivery of primary health care. They are the future of the pharmacy profession; therefore, it is critical that they are sufficiently trained and provided with the necessary resources to ensure high quality care in the management of drug misuse.
Australian Institute of Health and Welfare. The Third Australian Atlas of Healthcare Variation 2018 [Internet]. Canberra, ACT: AIHW, Australian Commission on Safety and Quality in Healthcare. Updated 2019. https://www.safetyandquality.gov.au/atlas/the-third-australian-atlas-of-healthcare-variation-2018. Accessed December 17, 2018.
International Pharmaceutical Federation (FIP). Reducing Harm Associated with Drugs of Abuse: The Role of Pharmacists. The Hague: International Pharmaceutical Federation; 2017:34.
The Pharmaceutical Society of Australia. Pharmacists in 2023: for Patients, for Our Profession, for Australia's Health System. Canberra, ACT: The Pharmaceutical Society of Australia; 2019:64.
Nicholas R, Lee N, Roche A. Pharmaceutical Drug Misuse Problems in Australia. Adelaide, SA: Flinders University, National Centre for Education and Training on Addiction (NCETA); 2011:114.
Nielsen S, Bruno R. Implementing real-time prescription drug monitoring: are we ready? Drug Alcohol Rev. 2014;33:464.
Gilmartin-Thomas JF, Bell JS, Liew D, et al. Chronic pain medication management of older populations: key points from a national conference and innovative opportunities for pharmacy practice. Res Social Adm Pharm. 2019;15:207-213.
Hulme S, Bright D, Nielsen S. The source and diversion of pharmaceutical drugs for non-medical use: a systematic review and meta-analysis. Drug Alcohol Depend. 2018;186:242-243, 247-248, 251-252.
Hollingworth SA, Gray PD, Hall WD, Najman JM. Opioid analgesic prescribing in Australia: a focus on gender and age. Pharmacoepidemiol Drug Saf. 2015;24:629-630, 633-635.
Department of Health and Human Services. Real-Time Prescription Monitoring [Internet]. Melbourne, Australia: Department of Health and Human Services, State Government Victoria. Updated 2017. http://www2.health.vic.gov.au/public-health/drugs-and-poisons/real-time-prescription-monitoring. Accessed August 25, 2017.
Department of Health and Human Services. Real-Time Prescription Monitoring: Frequently Asked Questions - For Health Professionals [Internet]. Melbourne, Australia: Department of Health and Human Services, State Government Victoria. Updated 2017. http://www2.health.vic.gov.au/public-health/drugs-and-poisons/real-time-prescription-monitoring. Accessed August 25, 2017.
Commonwealth of Australia - Department of Health 2017. National Drug Strategy 2017-2026. Canberra, ACT: Department of Health; 2017:52.
Khalil H, Peters M, Godfrey CM, McInerney P, Soares CB, Parker D. An evidence-based approach to scoping reviews. Worldviews Evid Based Nurs. 2016;13(2):118-122.
Arksey H, O'Malley L. Scoping studies: towards a methodological framework. Int J Soc Res Methodol. 2005;8(1):19-32.
The Joanna Briggs Institute. Joanna Briggs Institute Reviewers' Manual 2015. Methodology for JBI Scoping Reviews. Adelaide, SA: The Joanna Briggs Institute; 2015:24.
Peters MDJ, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):142.
Cochran G, Field C, Lawson K. Pharmacists who screen and discuss opioid misuse with patients: future directions for research and practice. J Pharm Pract. 2015;28(4):404-412.
Cochran G, Field C, Lawson K, Erickson C. Pharmacists' knowledge, attitudes and beliefs regarding screening and brief intervention for prescription opioid abuse: a survey of Utah and Texas pharmacists. J Pharm Health Serv Res. 2013;4:71-79.
Hagemeier NE, Murawski MM, Lopez NC, Alamian A, Pack RP. Theoretical exploration of Tennessee community pharmacists' perceptions regarding opioid pain relief abuse communication. Res Social Adm Pharm. 2014;10:562-575.
Fendrich M, Bryan JK, Hooyer K. Prescription drug monitoring programs and pharmacist orientation toward dispensing controlled substances. Subst Use Misuse. 2018;3:1-7.
Penm J, MacKinnon NJ, Boone JM, Ciaccia A, McNamee C, Winstanley EL. Strategies and policies to address the opioid epidemic: a case study of Ohio. J Am Pharm Assoc. 2017;57:148-153.
Lafferty L, Hunter TS, Marsh WA. Knowledge, attitudes and practices of pharmacists concerning prescription drug abuse. J Psychoactive Drugs. 2006;38(3):229-232.
Hagemeier NE, Tudiver F, Brewster S, Hagy EJ, Hagaman A, Pack RP. Prescription drug abuse communication: a qualitative analysis of prescriber and pharmacist perceptions and behaviours. Res Social Adm Pharm. 2016;12:937-948.
Hagemeier NE, Gray JA, Pack RP. Prescription drug abuse: a comparison of prescriber and pharmacist perspectives. Subst Use Misuse. 2013;48(9):783-790.
Wright J, Bond C, Robertson HD, Matheson C. Changes in over-the-counter drug misuse over 20 years: perceptions from Scottish pharmacists. J Public Health. 2015;38(4):793-799.
Bates G, Cochrane M, Mackridge AJ. The extent that health professionals suspect and address addiction to medicines in primary care: findings from a survey in Northwest England. J Addict Med. 2017;36(3):147-150.
Matheson C, Bond CM, Mollison J. Attitudinal factors associated with community pharmacists' involvement in services for drug misusers. Addiction. 1999;94(9):1349-1359.
MacFadyen L, Eadie D, McGowan T. Community pharmacists' experience of over-the-counter medicine misuse in Scotland. J R Soc Promot Health. 2001;121(3):185-192.
McBride AJ, Pates R, Ramadan R, McGowan C. Delphi survey of experts' opinions on strategies used by community pharmacists to reduce over-the-counter drug misuse. Addiction. 2003;98:487-497.
Gibbins AK, Wood PJ, Spark MJ. Managing inappropriate use of non-prescription combination analgesics containing codeine: a modified Delphi study. Res Social Adm Pharm. 2017;13:369-377.
Hamer AM, Spark MJ, Wood PJ, Roberts E. The upscheduling of combination analgesics containing codeine: the impact on the practice of pharmacists. Res Social Adm Pharm. 2014;10:669-678.
Patel T, Chang F, Mohammed HT, et al. Knowledge, perceptions and attitudes toward chronic pain and its management: a cross-sectional of frontline pharmacists in Ontario, Canada. PLOS One. 2016;7(1):1-14.
Leong C, Alessi-Severini S, Sareen J, Enns MW, Bolton J. Community pharmacists' perspectives on dispensing medications with the potential for misuse, diversion, and intentional overdose: results of a province-wide survey of community pharmacists in Canada. Subst Use Misuse. 2016;51(13):1724-1730.
Butler R, Sheridan J. Innocent parties or devious drug users: the views of primary healthcare practitioners with respect to those who misuse prescription drugs. Harm Reduct J. 2010;7(21):1-11.
Sheridan J, Butler R. Prescription drug misuse in New Zealand: challenges for primary health care professionals. Res Social Adm Pharm. 2011;7:281-293.
Liew D, Joules E, Booth J, Garrett K, Frauman A. Evidence to inform the inclusion of schedule 4 prescription medications on a real-time prescription monitoring system. Heidelberg, Vic.: Austin Health Department of Clinical Pharmacology and Therapeutics and Pharmacy Department; 2017;193:27-67.
Cochran GT, Engel RJ, Hruschak VJ, Tarter RE. Prescription opioid misuse among rural community pharmacy patients: pilot study for screening and implications for future practice and research. J Pharm Pract. 2017;30(5):502.
Ogell R, Hellbronn C, Lubman D. Prescription drug monitoring in Australia: capacity and coverage issues. Med J Aust. 2016;204(4):148.
Sproule B. Decreasing the harms of prescription opioids: a case for pharmacists. Drug and Alcohol Review. 2011;30:327.